Johnson & Johnson (JNJ): FY26 Q1 earnings call, Apr 14, 2026
On its Apr 14, 2026 earnings call (FY26 Q1), Johnson & Johnson said 9 of the 15 words Kalshi listed; Parrot’s count agreed with all 15 settlements. Quotes below are at most 25 words each, with timed clips.
UpdatedMarkets
15 words · 9 settled yes · our count agreed on 15 of 15- Kalshi: company speakers + operator
Kalshi
backtest The probabilities on settled rows are a walk-forward backtest: the model as of before each event, computed after Parrot went live; they were not published at the time.
| Word | Result | Our count | All speakers | Agrees | Probability | Clip | Market |
|---|---|---|---|---|---|---|---|
| Rybrevant | Yes | 5 | 5 | ✓ | 90%n=1+tx from settlement history blended with transcripts | Hear it 5:36, Rybrevant | – |
| Ottava | Yes | 5 | 5 | ✓ | 84%n=1+tx from settlement history blended with transcripts | Hear it 10:35, Ottava | – |
| Procedure | Yes | 3 | 3 | ✓ | 90%n=1+tx from settlement history blended with transcripts | Hear it 9:38, Procedure | – |
| Europe | Yes | 3 | 3 | ✓ | 82%n=1+tx from settlement history blended with transcripts | Hear it 9:32, Europe | – |
| Carvykti | Yes | 2 | 2 | ✓ | 92%n=1+tx from settlement history blended with transcripts | Hear it 5:03, Carvykti | – |
| China | Yes | 2 | 2 | ✓ | 87%n=1+tx from settlement history blended with transcripts | Hear it 18:11, China | – |
| Tariff | Yes | 2 | 2 | ✓ | 86%transcripts from the transcript model | Hear it 19:10, Tariff | – |
| Darzalex Faspro | Yes | 2 | 2 | ✓ | 18%n=1+tx from settlement history blended with transcripts | Hear it 5:23, Darzalex Faspro | – |
| Halda Therapeutics | Yes | 1 | 1 | ✓ | 53%n=1+tx from settlement history blended with transcripts | Hear it 43:39, Halda Therapeutics | – |
| Litigation | No | 0 | 0 | ✓ | 81%transcripts from the transcript model | – | |
| Administration | No | 0 | 0 | ✓ | 80%n=1+tx from settlement history blended with transcripts | – | |
| Nipocalimab / Lupus | No | 0 | 0 | ✓ | 54%n=1+tx from settlement history blended with transcripts | – | |
| Vaccine | No | 0 | 0 | ✓ | 20%n=1+tx from settlement history blended with transcripts | – | |
| AI / Artificial Intelligence | No | 0 | 0 | ✓ | 17%transcripts from the transcript model | – | |
| Trufill | No | 0 | 0 | ✓ | 13%n=1+tx from settlement history blended with transcripts | – |
Market prices are mid quotes from Kalshi and Polymarket, shown for context, may be delayed by several minutes and are not a signal. Quotes as of Oct 20, 2026 15:46 UTC.
Transcript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
3 matches for “Procedure”; 3 quoted, at least 25 words apart.
…electrophysiology was further strengthened by our recent launch of VARIPULSE Pro in Europe, with five times faster ablation, which helps streamline procedures and improve efficiency.
…enables surgeons to address cataract-related vision loss and presbyopia in a single procedure. In electrophysiology, VARIPULSE Pro is an innovative step forward, introducing a new…
…consistent with normal seasonal patterns. While there was some localized impact on procedure volume due to poor weather in parts of the business, we would…
Where the listed words were said
…potential new standard of care as early as second-line. In solid tumors, RYBREVANT FASPRO received FDA approval for subcutaneous monthly dosing for patients with EGFR-mutated…
…presence in the operating room. In Q1, we made progress on our OTTAVA Robotic Surgical System, and we are building on our recent De Novo…
…product, with sales of $4 billion and operational sales growth of 18%. CARVYKTI, TECVAYLI, and TALVEY also continue to deliver high double-digit growth, reflecting the…
…and competitive pressures in Energy and Endocutters, as well as VBP in China across the portfolio. In Vision, Contact Lenses and other products grew 2.7%,…
…Goods Sold deleveraged by 10 basis points, driven by the impact of tariffs and other operational drivers in the MedTech business, an unfavorable mix in…
…the community setting, as well as the U.S. approval of TECVAYLI plus DARZALEX FASPRO. TALVEY growth was 72.8%, driven by share gains through expansion in…
…remains early-stage deals like the one we did earlier this year with Halda Therapeutics, which brings a new platform in our oncology business. At the…
Agents: this page as TSV at /api/v1/appearances/johnson-and-johnson:2026-04-14:earnings_call · words: /api/v1/brief?appearance=johnson-and-johnson:2026-04-14:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP